September 2013 – Targeting Patient Fitness

Table of Contents

Download Journal

feb2014

Canadian Perspectives

dr-owen

Carolyn Owen, MD

Dr. Carolyn Owen completed postgraduate training in internal medicine and hematology at the University of Ottawa and the University of British Columbia, respectively, followed by a research fellowship in molecular genetics at Barts and the London School of Medicine and Dentistry in London, UK. Her research focused on familial myelodysplasia and acute myeloid leukemia. She is currently an Assistant Professor at the Foothills Medical Centre & Tom Baker Cancer Centre, and her clinical interests are low-grade lymphoma and chronic lymphocytic leukemia. She is also the local principal investigator in Calgary for several clinical trials in these areas.

dr-sehn

Laurie H. Sehn, MD, MPH

Dr. Laurie H. Sehn is a Clinical Assistant Professor at the BC Cancer Agency and the University of British Columbia in Vancouver. She has been a medical oncologist and clinical investigator with the Lymphoma Tumour Group since 1998. Dr. Sehn has served on the Board of Directors of Lymphoma Foundation Canada (LFC) since 2002 and is currently Director of Research Fellowships for the LFC. Dr. Sehn’s research interests include all of the lymphoid cancers, with particular interest in the biology and treatment of large-cell lymphoma, the application of new imaging techniques such as PET scanning to lymphoma management, and innovative new approaches to treatment.

dr-prchal

Jaroslav F. Prchal, MD

Dr. Jaroslav F. Prchal is an Associate Professor of Oncology and Medicine at McGill University, and Chair of the Department of Oncology at St. Mary’s Hospital Center in Montreal, Quebec, Canada. Dr. Prchal attended Charles University in Prague, receiving his Doctor of Medicine degree in 1964. He trained in Medicine at Toronto General Hospital and subsequently completed a post-graduate fellowship in Hematology at the University of Toronto and a Medical Research Council fellowship in Hematology and Marrow Transplantation in Seattle, Washington, USA. In 1979, he joined the staff at McGill University and the Royal Victoria Hospital, as well as St. Mary’s Hospital Center, where he has helped to build the Cancer Care program, serving as Chief of Oncology since 1997. Dr. Prchal’s main research interests include bone marrow disorders, specifically chronic myeloproliferative neoplasms, and his work has been published in journals such as Blood, the Journal of Clinical Investigation, Nature, and the New England Journal of Medicine.

International Perspectives

dr-sehn
Clemens-Martin Wendtner, MD
Clemens-Martin Wendtner, M.D., is Professor of Medicine and Director of the Department of Hematology, Oncology, Immunology, Palliative Care, Infectious Diseases and Tropical Medicine at the Klinikum Schwabing, Munich — an academic hospital of the University of Munich. He completed his M.D. at the University of Münster in 1993. Thereafter, he received postdoctoral training at the Max-Planck-Institute in Martinsried, Germany and at the National Institutes of Health (NIH) in Bethesda, USA, until 1995. After a clinical fellowship at the University of Munich, he gained his German and US licence (ECFMG) in Internal Medicine before specialising as a Hematologist and Oncologist at the same institution. Dr. Wendtner received his postdoctoral lecture qualification at the University of Munich in 2002, and since 2004, he is a full professor of Internal Medicine, Hematology, and Medical Oncology at the University of Cologne. Dr. Wendtner is a member of multiple national and international societies in the field of Medicine and has won several research awards, including first prize at the 6th International Symposium Biological Therapy of Cancer in Munich, and a merit award from the American Society of Clinical Oncology. As a founding member of the German CLL Study Group (GCLLSG), he participates on the Steering Committee and is Secretary of GCLLSG. He has been principal investigator for numerous phase I-III clinical studies, and his interests focus on the development of new therapies in the field of CLL.

Investigator Commentary

dr-lococo

Laurie H. Sehn, MD, MPH

Dr. Francesco Lo-Coco is a full Professor of Hematology and Head of the Laboratory of Integrated Diagnosis of Oncohematologic Diseases at the Department of Biopathology, University of Rome Tor Vergata, Rome, Italy. His main research activities include genetic characterization, monitoring, and treatment of hematologic tumours, particularly acute myeloid leukemia and acute promyelocytic leukemia (APL). He has served as President of the Italian Society of Experimental Hematology, been a board member of the Italian Foundation for Cancer Research, and a member of the Committee on Health Research at the Italian Ministry of Health. He is presently chairman of the APL subcommittee of the Italian National Cooperative Group GIMEMA, chairman of the Education Committee of the European Hematology Association, and a member of the editorial board for the journals Leukemia and Haematologica.

dr-goede

Valentin Goede, MD

Valentin Goede, M.D. is a Hematologist/Oncologist in the Department I of Internal Medicine at the University Hospital of Cologne, Cologne, Germany. He is also a Senior Physician and Consultant at the Department of Geriatric Medicine and Research at St. Marien Hospital, University of Cologne. After obtaining his M.D. at the University of Goettingen, Dr. Goede was trained in internal medicine at the Ammerland Clinic Westerstede. His hematology and oncology training was completed at the University Hospital Munich-Großhadern and the University Hospital of Cologne. His training in geriatric medicine was completed at the St. Marien Hospital, University of Cologne. Dr. Goede’s main research interest focuses on the prediction and management of age-related vulnerability in elderly patients with leukemia, lymphoma, and other types of cancer.